Zunveyl is a drug owned by Alpha Cognition Inc. It is protected by 4 US drug patents filed from 2024 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 26, 2044. Details of Zunveyl's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11795176 | Solid forms of Alpha-1062 gluconate |
Jan, 2042
(15 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12208176 | Process for making dry and stable hemostatic compositions |
Feb, 2044
(17 years from now) | Active |
| US12208167 | Coated tablets for pH-dependent release of benzgalantamine |
Feb, 2044
(17 years from now) | Active |
| US9763953 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
Dec, 2026
(8 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Zunveyl's patents.
Latest Legal Activities on Zunveyl's Patents
Given below is the list of recent legal activities going on the following patents of Zunveyl.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US9763953 |
| Information Disclosure Statement (IDS) Filed | 26 Aug, 2025 | US9763953 |
| transaction for FDA Determination of Regulatory Review Period | 01 Aug, 2025 | US9763953 |
| Mail Patent eCofC Notification | 01 Apr, 2025 | US12208167 |
| Patent eCofC Notification | 01 Apr, 2025 | US12208167 |
| Recordation of Patent eCertificate of Correction | 01 Apr, 2025 | US12208167 |
| Email Notification | 01 Apr, 2025 | US12208167 |
| Second letter to regulating agency to determine regulatory review period | 26 Mar, 2025 | US9763953 |
| Letter from FDA or Dept of Agriculture re PTE application | 17 Mar, 2025 | US9763953 |
| Mail Certificate of Correction Memo | 13 Mar, 2025 | US12208167 |
US patents provide insights into the exclusivity only within the United States, but
Zunveyl is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Zunveyl's family patents as well as insights into
ongoing legal events
on those patents.
Zunveyl's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zunveyl's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 26, 2044 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zunveyl Generics:
There are no approved generic versions for Zunveyl as of now.
About Zunveyl
Zunveyl is a drug owned by Alpha Cognition Inc. Zunveyl uses Benzgalantamine Gluconate as an active ingredient. Zunveyl was launched by Alpha Cognition in 2024.
Approval Date:
Zunveyl was approved by FDA for market use on 26 July, 2024.
Active Ingredient:
Zunveyl uses Benzgalantamine Gluconate as the active ingredient. Check out other Drugs and Companies using Benzgalantamine Gluconate ingredient
Dosage:
Zunveyl is available in tablet, delayed release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 5MG BASE | TABLET, DELAYED RELEASE | Prescription | ORAL |
| EQ 15MG BASE | TABLET, DELAYED RELEASE | Prescription | ORAL |
| EQ 10MG BASE | TABLET, DELAYED RELEASE | Prescription | ORAL |